In people with type 1 diabetes, the pancreas does not make insulin — a hormone that helps glucose get into your cells to give them energy — which is why they take insulin. In Type 2 diabetes people, the body does not make or use insulin well, and so insulin therapy may be needed. Daily insulin shots for the management of diabetes could become a thing of the past, and insulin pills now are another option for diabetes patients. Diabetes ranks among the fast-growing chronic diseases in the United States. The prevailing cases of diabetes in the US are largely due to rising obesity levels, which is mainly due to their sedentary lifestyles, physical inactivities, unhealthy eating habits, and an increasingly aging population.
The diabetes drugs industry held the largest market share in the North American pharmaceutical sector due to the increasing prevalence of diabetes in this region and the presence of a high-quality health care system, which are the most influencing factors driving the market for diabetes drugs. It has proved that one in ten people in the country has diabetes, and it is expected to take the situation to one in three by 2050 by the rise in trends. The research and development are growing year on year in the insulin segments where researchers are trying to bring out the best molecule for patients use, suppressing the maximum side effects and increasing its efficiency. Better accessibility to treatment therapies and the presence of favorable reimbursement programs will result in a high turnout of patients opting for diabetes treatment. This will, in turn, fuel the growth of the US insulin market size during the next few years. Based on nanotechnology, innumerable research efforts are being made to develop pH-sensitive hydrogels, a three-dimensional network polymer structure that resembles those of the body tissues or cells that will encapsulate insulin in its cage and release the insulin through swelling and de-swelling mechanisms into the intestine.
The market research analysis presents a detailed segmentation of the oral insulin market by drug class (intermediate-acting, fast-acting, and long-acting), by the application (type 1 and type 2 diabetes). Type 2 diabetes is the largest segment of the global oral insulin market in terms of application. Based on regions, currently, urban areas consist of most of the diabetes patients as compared to rural areas. Based on gender, presently, females are accounting for the majority of the total diabetes patients. In terms of age groups, the age group 40-59 currently accounts for the majority of the total diabetes patients, followed by the age group 60-79 and 20-39 in the US.
Several pharmaceutical companies are now coming up with drugs that will use different therapeutic approaches to treat diabetes, besides developing new insulin-based products. For instance, Diabetes is a cell therapy-based product that secretes insulin on detecting elevated glucose levels. Recently, the increase in research activities for novel products will aid in the growth of the insulin market size in the US during the forecast period. Insulin Tregopil is the first oral insulin, which is under development by Biocon India. Zynquista (sotagliflozin) would be the first oral antidiabetic drug that has been approved in the U.S. SAR341402, the biosimilar version of Insulin Aspart, is under clinical trials studies by Sanofi.
Some of the few key players involved in the global oral insulin market include Abbott Laboratories, GlySens Incorporated, Echo Therapeutics Inc., Sanofi, Medtronic Plc, Novo Nordisk, Hoffmann-La Roche Ltd., MannKind Corporation, Dexcom Inc., and Senseonics Holding Inc.